Abstract
Herein the discovery of a novel class of aminoheterocyclic Na(v)1.7 antagonists is reported. Hit compound 1 was potent but suffered from poor pharmacokinetics and selectivity. The compact structure of 1 offered a modular synthetic strategy towards a broad structure-activity relationship analysis. This analysis led to the identification of aminopyrazine 41, which had vastly improved hERG selectivity and pharmacokinetic properties.
Copyright © 2012 Elsevier Ltd. All rights reserved.
MeSH terms
-
Amines / chemistry
-
Amines / metabolism
-
Amines / pharmacokinetics
-
Amines / pharmacology
-
Animals
-
Drug Discovery
-
Inhibitory Concentration 50
-
Male
-
NAV1.7 Voltage-Gated Sodium Channel
-
Plasma / metabolism
-
Pyrazines / chemistry*
-
Pyrazines / metabolism
-
Pyrazines / pharmacokinetics
-
Pyrazines / pharmacology*
-
Rats
-
Rats, Sprague-Dawley
-
Sodium Channel Blockers / chemistry*
-
Sodium Channel Blockers / metabolism
-
Sodium Channel Blockers / pharmacokinetics
-
Sodium Channel Blockers / pharmacology*
-
Sodium Channels / metabolism*
-
Structure-Activity Relationship
Substances
-
Amines
-
NAV1.7 Voltage-Gated Sodium Channel
-
Pyrazines
-
SCN9A protein, human
-
Sodium Channel Blockers
-
Sodium Channels